Volgen
Pradnya Patil
Pradnya Patil
Geverifieerd e-mailadres voor ccf.org
Titel
Geciteerd door
Geciteerd door
Jaar
Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ...
Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022
2662022
Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non–small cell lung cancer
M Khorrami, P Prasanna, A Gupta, P Patil, PD Velu, R Thawani, ...
Cancer immunology research 8 (1), 108-119, 2020
2562020
Primary pulmonary artery sarcoma: a close associate of pulmonary embolism—20-year observational analysis
D Bandyopadhyay, TS Panchabhai, NS Bajaj, PD Patil, MC Bunte
Journal of thoracic disease 8 (9), 2592, 2016
1232016
CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective …
P Vaidya, K Bera, A Gupta, X Wang, G Corredor, P Fu, N Beig, ...
The Lancet Digital Health 2 (3), e116-e128, 2020
1182020
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
F Skoulidis, KC Arbour, MD Hellmann, PD Patil, ME Marmarelis, ...
Journal of Clinical Oncology 37 (15_suppl), 102-102, 2019
1122019
Combination of peri-and intratumoral radiomic features on baseline CT scans predicts response to chemotherapy in lung adenocarcinoma
M Khorrami, M Khunger, A Zagouras, P Patil, R Thawani, K Bera, P Rajiah, ...
Radiology: Artificial Intelligence 1 (2), 180012, 2019
1092019
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
P Vaidya, K Bera, PD Patil, A Gupta, P Jain, M Alilou, M Khorrami, ...
Journal for Immunotherapy of Cancer 8 (2), 2020
902020
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ...
Cancer discovery 13 (7), 1556-1571, 2023
822023
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
M Khunger, PD Patil, A Khunger, M Li, B Hu, S Rakshit, A Basu, N Pennell, ...
PloS one 13 (10), e0197743, 2018
742018
Managing human bites
PD Patil, TS Panchabhai, SC Galwankar
Journal of Emergencies, Trauma, and Shock 2 (3), 186-190, 2009
702009
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features
M Khorrami, P Jain, K Bera, M Alilou, R Thawani, P Patil, U Ahmad, ...
Lung Cancer 135, 1-9, 2019
692019
An autopsy study of maternal mortality: a tertiary healthcare perspective
TS Panchabhai, PD Patil, DR Shah, AS Joshi
Journal of postgraduate medicine 55 (1), 8-11, 2009
532009
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
K Jazieh, M Khorrami, A Saad, M Gad, A Gupta, P Patil, VS Viswanathan, ...
Journal for Immunotherapy of Cancer 10 (3), 2022
422022
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study
M Khorrami, K Bera, P Leo, P Vaidya, P Patil, R Thawani, P Velu, P Rajiah, ...
Lung Cancer 142, 90-97, 2020
422020
Perioperative systemic therapy for resectable non–small cell lung cancer
B Muthusamy, PD Patil, NA Pennell
Journal of the National Comprehensive Cancer Network 20 (8), 953-961, 2022
382022
RaPtomics: integrating radiomic and pathomic features for predicting recurrence in early stage lung cancer
P Vaidya, X Wang, K Bera, A Khunger, H Choi, P Patil, V Velcheti, ...
Medical Imaging 2018: Digital Pathology 10581, 172-182, 2018
322018
Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).
B Thapa, J Roopkumar, AS Kim, L Gervaso, PD Patil, C Calabrese, ...
Journal of Clinical Oncology 37 (15_suppl), e14151-e14151, 2019
302019
OA09. 03 Pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-positive non-small cell lung Cancer (NSCLC)
S Gadgeel, K Dziubek, M Nagasaka, T Braun, K Hassan, H Cheng, ...
Journal of Thoracic Oncology 16 (10), S863, 2021
272021
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead
PD Patil, M Burotto, V Velcheti
Expert review of molecular diagnostics 18 (3), 297-305, 2018
262018
Pulmonary artery pseudoaneurysm: a rare cause of fatal massive hemoptysis
H Koneru, S Biswas Roy, M Islam, H Abdelrazek, D Bandyopadhyay, ...
Case Reports in Pulmonology 2018 (1), 8251967, 2018
252018
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20